Celyad Oncology SA American Depositary Shares
CYAD
CYAD was delisted on the 18th of May, 2023.
10 hedge funds and large institutions have $20.4M invested in Celyad Oncology SA American Depositary Shares in 2017 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
100% more funds holding
Funds holding: 5 → 10 (+5)
8% more capital invested
Capital invested by funds: $18.9M → $20.4M (+$1.57M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
+$5.93M |
| 2 |
Jane Street
New York
|
+$313K |
| 3 |
Renaissance Technologies
New York
|
+$263K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$175K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$8.64K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$221K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Victory Capital Management
San Antonio,
Texas
| $19.5M | +$5.93M | +118,590 | +36% |
|
|
2
Morgan Stanley
New York
| $265K | -$221K | -4,425 | -42% |
|
|
3
Jane Street
New York
| $260K | +$313K | +6,254 | New |
|
|
4
Renaissance Technologies
New York
| $227K | +$263K | +5,260 | New |
|
|
5
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $150K | +$175K | +3,500 | New |
|
|
6
UBS Group
Zurich,
Switzerland
| $46K | +$8.64K | +173 | +20% |
|
|
TRCT
7
Tower Research Capital (TRC)
New York
| $6K | +$5.95K | +119 | +410% |
|
8
Zurich Cantonal Bank
Zurich,
Switzerland
| $4K | – | – | – |
|
9
Bank of Montreal
Toronto,
Ontario, Canada
| $4K | +$4.35K | +87 | New |
|
|
II
10
Inspire Investing
Meridian,
Idaho
| $1K | +$1.05K | +21 | New |
|
CYAD Hedge Fund Activity: Q4 2017 in Review
10 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Celyad Oncology SA American Depositary Shares (CYAD) for Q4 2017, worth a combined $20.4M — up 8.3% from $18.9M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new CYAD positions and 0 closed out — a net gain of 5 holders — while 3 added to existing stakes and 1 trimmed.
The largest buyer was Victory Capital Management, adding an estimated $5.93M. The largest seller was Morgan Stanley, cutting an estimated $221K.
- 10 institutional investors held Celyad Oncology SA American Depositary Shares (CYAD) as of Q4 2017, up from 5 in Q3 2017.
- Funds reported $20.4M of Celyad Oncology SA American Depositary Shares stock for Q4 2017, up 8.3% quarter-over-quarter.
- 5 funds opened new Celyad Oncology SA American Depositary Shares positions in Q4 2017 and 0 closed out, a net change of +5 holders.
- The largest Celyad Oncology SA American Depositary Shares buyer in Q4 2017 was Victory Capital Management, an estimated $5.93M added.
- The largest Celyad Oncology SA American Depositary Shares seller in Q4 2017 was Morgan Stanley, an estimated $221K sold.
Based on aggregated 13F filings for Q4 2017.